We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Visa (V) Tops Quarterly Estimates, Earnings Surge 30%
Read MoreHide Full Article
Visa (V - Free Report) just released its second quarter 2018 financial results, posting adjusted earnings of $1.11 per share and revenues of $5.07 billion.
Visa is currently a Zacks Rank #3 (Hold). Shares of Visa are up 31% over the last year and 3% in the last month. Visa experienced a marginal decline on Wednesday to hit $121.20 per share prior to the release of its quarterly earnings results.
Visa stock is currently up 1.89% to $123.50 per share in after-hours trading shortly after its earnings report was released.
V:
Beat earnings estimates. The company posted adjusted earnings of $1.11 per share, beating the Zacks Consensus Estimate of $1.01 per share.
Beat revenue estimates. The company saw revenue figures of $5.07 billion, topping our consensus estimate of $4.78 billion.
Visa’s quarterly revenues jumped roughly 13% from the year-ago period. Meanwhile, the credit card giant’s quarterly earnings climbed 30%.
Visa noted that its payments volume jumped by 11%, while processed transactions climbed 12%. The company also repurchased 16.9 million shares of class A common stock during the quarter.
Here’s a graph that looks at Visa’s Price, Consensus and EPS Surprise history:
Check back later for our full analysis on Visa’s earnings report!
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Image: Bigstock
Visa (V) Tops Quarterly Estimates, Earnings Surge 30%
Visa (V - Free Report) just released its second quarter 2018 financial results, posting adjusted earnings of $1.11 per share and revenues of $5.07 billion.
Visa is currently a Zacks Rank #3 (Hold). Shares of Visa are up 31% over the last year and 3% in the last month. Visa experienced a marginal decline on Wednesday to hit $121.20 per share prior to the release of its quarterly earnings results.
Visa stock is currently up 1.89% to $123.50 per share in after-hours trading shortly after its earnings report was released.
V:
Beat earnings estimates. The company posted adjusted earnings of $1.11 per share, beating the Zacks Consensus Estimate of $1.01 per share.
Beat revenue estimates. The company saw revenue figures of $5.07 billion, topping our consensus estimate of $4.78 billion.
Visa’s quarterly revenues jumped roughly 13% from the year-ago period. Meanwhile, the credit card giant’s quarterly earnings climbed 30%.
Visa noted that its payments volume jumped by 11%, while processed transactions climbed 12%. The company also repurchased 16.9 million shares of class A common stock during the quarter.
Here’s a graph that looks at Visa’s Price, Consensus and EPS Surprise history:
Visa Inc. Price, Consensus and EPS Surprise
Visa Inc. Price, Consensus and EPS Surprise | Visa Inc. Quote
Check back later for our full analysis on Visa’s earnings report!
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>